Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(2):90-91; doi:10.1093/jnci/djj045
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Whitworth, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitworth, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Recent Research Highlights Importance of Trials Halted 10 Years Ago

Ariel Whitworth

The first 10% of the full text of this article appears below.

Ten years ago, investigators from two large clinical trials ended their studies early—for entirely different reasons. For researchers heading the beta-Carotene and Retinol Efficacy Trial (CARET), intervention stopped in January 1996 when scientists observed that current and former smokers taking beta-carotene and vitamin A supplements—hypothesized to reduce cancer risk—were developing lung cancer at a higher rate than participants taking a placebo. A couple of months earlier, the National Surgical Adjuvant Breast and Bowel Project (NSABP) decided to halt its study of long-term use of tamoxifen for breast cancer treatment when scientists discovered that tamoxifen provided no additional benefit after 5 years of treatment.

beta-Carotene: Beneficial or Harmful?

"We have . . . [Full Text of this Article]

After Tamoxifen, What Next?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?